

Hermann Toplak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5990834/hermann-toplak-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

3,012
citations

25
h-index

54
g-index

92
ext. papers

3,867
ext. citations

5.2
avg, IF

4.89
L-index

#	Paper	IF	Citations
67	High-Protein, Low-Glycaemic Meal Replacement Decreases Fasting Insulin and Inflammation Markers-A 12-Month Subanalysis of the ACOORH Trial. <i>Nutrients</i> , 2021 , 13,	6.7	2
66	Meal replacement by formula diet reduces weight more than a lifestyle intervention alone in patients with overweight or obesity and accompanied cardiovascular risk factors-the ACOORH trial. <i>European Journal of Clinical Nutrition</i> , 2021 , 75, 661-669	5.2	8
65	Underestimation of resting metabolic rate using equations compared to indirect calorimetry in normal-weight subjects: Consideration of resting metabolic rate as a function of body composition. <i>Clinical Nutrition Open Science</i> , 2021 , 35, 48-66		1
64	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe [Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , 2021 , 43, 24-30		2
63	Effects of a Protein-Rich, Low-Glycaemic Meal Replacement on Changes in Dietary Intake and Body Weight Following a Weight-Management Intervention-The ACOORH Trial. <i>Nutrients</i> , 2021 , 13,	6.7	2
62	Reproductive outcomes after bariatric surgery in women. <i>Wiener Klinische Wochenschrift</i> , 2021 , 134, 56	2.3	2
61	Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1419-1425	2.5	1
60	Prediabetes Conversion to Normoglycemia Is Superior Adding a Low-Carbohydrate and Energy Deficit Formula Diet to Lifestyle Intervention-A 12-Month Subanalysis of the ACOORH Trial. <i>Nutrients</i> , 2020 , 12,	6.7	9
59	European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. <i>Obesity Facts</i> , 2019 , 12, 40-66	5.1	120
58	The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. <i>Obesity Facts</i> , 2019 , 12, 131-136	5.1	66
57	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia <i>Journal of Hypertension</i> , 2018 , 36, 1441-1455	1.9	48
56	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. <i>Journal of Hypertension</i> , 2018 , 36, 1441-1455	1.9	26
55	Obesity Management Task Force of the European Association for the Study of Obesity Released "Practical Recommendations for the Post-Bariatric Surgery Medical Management". <i>Obesity Surgery</i> , 2018 , 28, 2117-2121	3.7	45
54	Sarcopenic Obesity: Time to Meet the Challenge. <i>Obesity Facts</i> , 2018 , 11, 294-305	5.1	68
53	Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2670-2674	6.7	7
52	Clinical-Pathological Conference Series from the Medical University of Graz : Case No 153: A 55-year-old woman with atypical multiple sclerosis and irritable bowel syndrome. <i>Wiener Klinische Wochenschrift</i> , 2018 , 130, 151-160	2.3	1
51	Sarcopenic obesity: Time to meet the challenge. <i>Clinical Nutrition</i> , 2018 , 37, 1787-1793	5.9	68

50	Two-Stage Evaluation of a Telehealth Nutrition Management Service in Support of Diabetes Therapy. <i>Studies in Health Technology and Informatics</i> , 2018 , 248, 314-321	0.5	2
49	Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way. <i>Obesity Facts</i> , 2017 , 10, 483-492	5.1	124
48	A Proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk. <i>Obesity Facts</i> , 2017 , 10, 284-307	5.1	41
47	Was sind Barrieren der Ernährungstherapie bei mangelernährten, hospitalisierten Patienten der Inneren Medizin?. <i>Aktuelle Ernährungsmedizin Klinik Und Praxis</i> , 2017 , 42, 167-179	0.3	
46	Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. <i>Obesity Facts</i> , 2017 , 10, 597-632	5.1	177
45	Comment on the Paper by Uerlich et al: Obesity Management in Europe: Current Status and Objectives for the Future. <i>Obes Facts</i> 2016;9:273-283. <i>Obesity Facts</i> , 2016 , 9, 392-396	5.1	3
44	2015 Milan Declaration: A Call to Action on Obesity - an EASO Position Statement on the Occasion of the 2015 EXPO. <i>Obesity Facts</i> , 2016 , 9, 296-8	5.1	8
43	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. <i>Wiener Klinische Wochenschrift</i> , 2016 , 128 Suppl 2, S216-28	2.3	4
42	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. <i>Journal of Hypertension</i> , 2016 , 34, 1678-88	1.9	8
41	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects. <i>Diabetologia</i> , 2016 , 59, 1148-9	10.3	15
40	Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. <i>International Journal of Cardiology</i> , 2015 , 184, 710-716	3.2	19
39	Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing. <i>Journal of Hypertension</i> , 2015 , 33, 425-34	1.9	22
38	Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotoxic steroid with clinical and diagnostic implications. <i>Clinical and Experimental Hypertension</i> , 2015 , 37, 108-15	2.2	13
37	European Guidelines for Obesity Management in Adults. <i>Obesity Facts</i> , 2015 , 8, 402-24	5.1	509
36	2014 EASO Position Statement on the Use of Anti-Obesity Drugs. <i>Obesity Facts</i> , 2015 , 8, 166-74	5.1	33
35	Interview mit Univ.-Prof. Dr. Hermann Toplak zu Fragen der Ernährung. <i>Deutsche Zeitschrift für Akupunktur</i> , 2015 , 58, 14-17	0.1	0
34	New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2014 , 126, 169-75	2.3	14
33	Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 20-31	12.7	111

32	An EASO position statement on multidisciplinary obesity management in adults. <i>Obesity Facts</i> , 2014 , 7, 96-101	5.1	49
31	Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. <i>Diabetes Care</i> , 2014 , 37, 912-21	14.6	130
30	Need for a paradigm shift in adult overweight and obesity management - an EASO position statement on a pressing public health, clinical and scientific challenge in Europe. <i>Obesity Facts</i> , 2014 , 7, 408-16	5.1	23
29	Are there differences in LDL-C target value attainment in Austrian federal states? Yes!. <i>Wiener Medizinische Wochenschrift</i> , 2013 , 163, 528-35	2.9	1
28	Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. <i>Obesity Facts</i> , 2013 , 6, 117-20	5.1	144
27	Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group). <i>Neuropsychiatric Disease and Treatment</i> , 2012 , 8, 355-60	3.1	6
26	Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. <i>Obesity Facts</i> , 2012 , 5, 460-83	5.1	171
25	Criteria for EASO-collaborating centres for obesity management. <i>Obesity Facts</i> , 2011 , 4, 329-33	5.1	25
24	Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). <i>Neuropsychiatric Disease and Treatment</i> , 2009 , 5, 261-6	3.1	12
23	Fat or fit: what is more important?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S392-7	14.6	61
22	Management of obesity in adults: European clinical practice guidelines. <i>Obesity Facts</i> , 2008 , 1, 106-16	5.1	241
21	A pilot study of mobile phone-based therapy for obese patients. <i>Journal of Telemedicine and Telecare</i> , 2008 , 14, 147-9	6.8	31
20	Treatment modalities of obesity: what fits whom?. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S269-77	14.6	135
19	Effects of orlistat therapy on plasma concentrations of oxygenated and hydrocarbon carotenoids. <i>Lipids</i> , 2006 , 41, 113-8	1.6	7
18	Histopathologic changes after intralesional application of phosphatidylcholine for lipoma reduction: report of a case. <i>American Journal of Dermatopathology</i> , 2006 , 28, 331-3	0.9	15
17	Clinical-pathological conference series from the Medical University of Graz : case no. 131: elevated transaminases in a 30-year-old male. <i>Wiener Klinische Wochenschrift</i> , 2006 , 118, 769-75	2.3	0
16	Intralesional lipolysis with phosphatidylcholine for the treatment of lipomas: pilot study. <i>Archives of Dermatology</i> , 2006 , 142, 395-6		24
15	Evaluation of a new DNA test compared with the lactose hydrogen breath test for the diagnosis of lactase non-persistence. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 371-6	2.2	66

14	A novel splice-site mutation in intron 7 causes more severe hypercholesterolemia than a combined FH-FDB defect. <i>Atherosclerosis</i> , 2001 , 157, 524-5	3.1	4
13	Factor II G20210A and Factor V G1691A Gene Mutations and Peripheral Arterial Occlusive Disease. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 20-22	7	25
12	Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. <i>Thrombosis Research</i> , 2000 , 99, 35-9	8.2	47
11	C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. <i>Atherosclerosis</i> , 2000 , 152, 175-9	3.1	20
10	CAPRIE trial. <i>Lancet, The</i> , 1997 , 349, 354; author reply 356	40	3
9	Prevalence of coronary artery disease in obese versus lean men with angina pectoris and positive exercise stress test. <i>American Journal of Cardiology</i> , 1996 , 77, 1000-1	3	9
8	Insulin resistance and membrane abnormalities. <i>Lancet, The</i> , 1995 , 345, 994-995	40	6
7	Endothelial dysfunction in hypertension. <i>Lancet, The</i> , 1994 , 344, 549-50	40	4
6	Cellular accumulation of amiodarone and desethylamiodarone in cultured human cells. Consequences of drug accumulation on cellular lipid metabolism and plasma membrane properties of chronically exposed cells. <i>Biochemical Pharmacology</i> , 1993 , 45, 349-56	6	29
5	Cultured human skin fibroblasts modify their plasma membrane lipid composition and fluidity according to growth temperature suggesting homeoviscous adaptation at hypothermic (30 degrees C) but not at hyperthermic (40 degrees C) temperatures. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1992 , 1104, 31-7	3.8	21
4	Lipoprotein (a) is not a risk factor for restenosis after percutaneous transluminal coronary angioplasty. <i>American Journal of Cardiology</i> , 1992 , 69, 572	3	8
3	Increased IgM-anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty. <i>American Journal of Cardiology</i> , 1992 , 69, 1255-8	3	28
2	Single and multiple desipramine exposures of cultured cells. Changes in cellular anisotropy and in lipid composition of whole cells and of plasma membranes. <i>Biochemical Pharmacology</i> , 1990 , 39, 1437-43	6	22
1	Effects of culture and incubation conditions on membrane fluidity in monolayers of cultured cells measured as fluorescence anisotropy using trimethylammoniumdiphenylhexatriene (TMA-DPH). <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1990 , 1028, 67-72	3.8	21